Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CARRY WEALTH HOLDINGS LIMITED
恒富控股有限公司
(Incorporated in Bermuda with limited liability)
Website: http://www.carrywealth.com
(Stock Code: 643)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of Carry Wealth Holdings Limited (the "**Company**") hereby announces that with effect from 30 June 2026, Mr. Li Xiaoming (黎曉明) ("**Mr. Li**") is appointed as an executive Director of the Company.

Set out below is the biographical details of Mr. Li:

Mr. Li, aged 43, obtained a bachelor's degree in materials science and engineering from East China Institute of Technology (now East China University of Technology) in 2006 and a master's degree in materials physics and chemistry from Fuzhou University in 2009. He also enrolled in the EMBA program at Cheung Kong Graduate School of Business in October 2024.

Mr. Li has been focusing on early-to-mid-stage healthcare and biomedical venture capital investments, with extensive experience in life sciences, biotechnology, AI healthcare, innovative drugs, and novel medical devices, and has successfully invested in over 30 medical projects. He has also been focusing on the intersection of AI and healthcare, with a particular emphasis on research and investment in AI applications across radiology, pathology, multi-omics, molecular compound screening, and intelligent rehabilitation. From April 2009 to September 2014, he worked at Guangdong Biolight Meditech Co., Ltd. (Stock Code: 300246), a company listed on the Shenzhen Stock Exchange, with the last position as deputy general manager. He was the director of Tianjin Baolaite Medical Technology Co., Ltd.* (天津寶萊特醫用科技有限公司) for the period between November 2013 to December 2025; the director of Shenzhen Yikang Tailai Technology Co., Ltd.* (深圳市益康泰來科技有限公司) for the period between December 2015 to July 2021; and the director of Shenzhen Jiahua Hospital Management Co., Ltd.*(深圳市嘉華醫院管理有限公司) for the period between

April 2017 to December 2022. He has been the general manager and chairman of Shenzhen Yanghe Biomedicine Industry Investment Co., Ltd. (深圳市陽和生物醫藥產業投資有限公司) since October 2014; the director of Guangzhou Liangyi Information Technology Co., Ltd* (廣州良醫信息科技有限公司) since July 2019 and the director of Guangzhou OO Medical Technology Co., Ltd.*(廣州歐歐醫療科技有限責任公司) since August 2019.

Mr. Li was appointed as a non-independent director of Nanjing Vishee Medical Technology Co., Ltd. (Shanghai Stock Exchange Stock Code: 688580) from November 2021 to November 2024; and has been appointed as a non-independent director of Guangdong Biolight Meditech Co., Ltd. (Shenzhen Stock Exchange Stock Code: 300246) since May 2020.

The Company has entered into a service contract with Mr. Li regarding his directorship for an initial term of three years. His appointment is subject to retirement by rotation and re-election pursuant to the the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the bye-laws of the Company. Pursuant to the service contract, Mr. Li is entitled to a fixed monthly Director's remuneration of HK$30,000, which was determined by the Board with reference to the recommendations from the Remuneration Committee, after taking into account multiple factors, including his position and responsibilities within the Company, his qualification, experience and remuneration level of market peers.

Prior to his appointment, Mr. Li has obtained legal advice as regards the requirements under the Listing Rules that is applicable to him as a director of a listed issuer. Mr. Li fully understands his duties and obligations as a Director under the Listing Rules and he will use his best endeavours to fulfill and discharge his duties as a Director going forward.

Save as disclosed above, as at the date of this announcement, Mr. Li (i) does not have any other interests in the shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance); (ii) does not hold any other position within the Company or its subsidiaries; (iii) does not have any other relationship with any Director, senior management, substantial shareholder or controlling shareholder; and (iv) did not hold any directorship in any public companies listed in Hong Kong or overseas in the past three years.

Save as disclosed above, there is no other information subject to disclosure under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, nor are there other matters relating to the appointment of Mr. Li that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warmest welcome to Mr. Li for joining the Board.

By order of the Board
Carry Wealth Holdings Limited
Lee Chi Ho
Executive Director

Hong Kong, 30 June 2026

As at the date of this announcement, the Board comprises Mr. Li Xiaoming and Mr. Lee Chi Ho as executive Directors and Mr. Lam Chi Wing and Ms. Li Qian as independent non-executive Directors.